RBC Units and Hemolysis: The Quality Indicator that Says it All
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, posted on LinkedIn:
”RBC Units and Hemolysis: the quality indicator that says it all
Red Blood Cell (RBC) concentrates are among the most sensitive blood components. Their integrity is shaped at every step of the transfusion chain – and hemolysis remains the most telling indicator of overall product quality.
International guidelines are clear:
• ≤ 0.8 % hemolysis at end of storage (European standards)
• ≤ 1 5according to AABB guidelines
These thresholds highlight the importance of protecting the erythrocyte membrane from cumulative stress.
1. Mechanical factors
Red cells are highly sensitive to physical stress:
• Too fast transfer of the RBC concentrate through the break-away cannula
• Kinking of the tubing during component separation
• Overly aggressive or poorly calibrated centrifugation
• Wrong sampling procedure
Such mechanical stresses create micro-lesions that can significantly increase hemolysis during storage.
2. Thermal factors
Thermal control is critical:
• Storage temperature too low
• Repeated fluctuations in the cold chain
• Thermal shock during collection or environmental transitions
Rapid variations weaken membrane stability and increase permeability.
3. Storage-related factors
Over time, several changes accumulate:
• Insufficient mixing with anticoagulant during collection
• Medium acidification
• Increased oxidative stress
• Reduced ATP levels, essential for membrane flexibility and resilience
Controlling hemolysis means protecting the RBC unit at every moment. A small percentage… that speaks volumes about quality.”
Stay updated with Hemostasis Today.
-
Dec 12, 2025, 23:51Don’t Miss: IACH Post ASH 2025 Roundtable Debate
-
Dec 12, 2025, 23:37C-Reactive Protein and Cardiovascular Risk in the General Population: A European Heart Journal Study by Berkan Kurt et al.
-
Dec 12, 2025, 23:23Alta Schutte and Colleagues at National Hypertension Taskforce: Driving Single-Pill Therapy for Hypertension and More
-
Dec 12, 2025, 22:27Normal Counts, High Risk: Abdul Mannan Breaks Down JAK2 + Splanchnic Vein Thrombosis
-
Dec 12, 2025, 14:478 Posts Not to Miss From the ASH 2025 – Marc Carrier
-
Dec 12, 2025, 10:17Alyssa George on Clinical and Economic Impact of a Eptacog Beta
-
Dec 12, 2025, 09:53Ivan Budnik Awarded AHA Postdoctoral Fellowship! Aiming to Improve DVT Long-term Outcomes
-
Dec 12, 2025, 09:34Giles Platford on Baby Big: Plasma-Derived Drug Against Infant Botulism
-
Dec 12, 2025, 09:22Matteo Foschi Presents The New Expert Guidance on Minor Ischemic Stroke